Phase 2 Type 2 Diabetes Trial, Recruiting (NCT07589608)

Phase 2 Type 2 Diabetes Trial, Recruiting NCT07589608 Sponsor: Eli Lilly and Company Condition: Type 2 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT07589608 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 2 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who meet the inclusion criteria listed in a related "master" trial (NCT06143956) — confirm the specific requirements directly with the trial site
People whose other regular medications have been at a stable, unchanged dose for at least 3 months before the screening visit

Who may not be able to join:

People who have type 1 or type 2 diabetes
People who have a history of a slow or irregular heart rhythm condition (such as bradyarrhythmia or sinus bradycardia)
People whose resting heart rate is above 100 beats per minute or below 60 beats per minute
People who have a history of pancreatitis (inflammation of the pancreas), whether it occurred once suddenly or as an ongoing condition
People who meet any of the additional exclusion criteria listed in the related master trial (NCT06143956) — confirm the full list with the trial site

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 15 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Phone: 317-615-4559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07589608

Sponsor: Eli Lilly and Company

Phase: Phase 2

Status: Recruiting

Condition: Type 2 Diabetes

Trial contact: 317-615-4559

More information: https://clinicaltrials.gov/study/NCT07589608

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who meet the inclusion criteria listed in a related "master" trial (NCT06143956) — confirm the specific requirements directly with the trial site
People whose other regular medications have been at a stable, unchanged dose for at least 3 months before the screening visit

Who may not be able to join:

People who have type 1 or type 2 diabetes
People who have a history of a slow or irregular heart rhythm condition (such as bradyarrhythmia or sinus bradycardia)
People whose resting heart rate is above 100 beats per minute or below 60 beats per minute
People who have a history of pancreatitis (inflammation of the pancreas), whether it occurred once suddenly or as an ongoing condition
People who meet any of the additional exclusion criteria listed in the related master trial (NCT06143956) — confirm the full list with the trial site

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 15 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Eli Lilly and Company

Registry

ClinicalTrials.gov

Start date

15 May 2026

Est. completion

1 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Percent Change from Baseline in Body Weight

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov